HC Wainwright reiterated their hold rating on shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) in a research report report published on Wednesday morning. The firm currently has a $17.00 price objective on the specialty pharmaceutical company’s stock.

VRX has been the topic of a number of other research reports. Wells Fargo & Company dropped coverage on shares of Valeant Pharmaceuticals International in a research note on Sunday, July 30th. BidaskClub downgraded shares of Valeant Pharmaceuticals International from a hold rating to a sell rating in a research note on Friday, June 16th. Vetr downgraded shares of Valeant Pharmaceuticals International from a strong-buy rating to a sell rating and set a $13.30 price target on the stock. in a research note on Thursday, August 24th. Stifel Nicolaus reiterated a buy rating and set a $35.00 price target on shares of Valeant Pharmaceuticals International in a research note on Friday, June 30th. Finally, ValuEngine downgraded shares of Valeant Pharmaceuticals International from a buy rating to a hold rating in a research note on Friday, September 1st. Five investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of Hold and an average target price of $17.73.

Valeant Pharmaceuticals International (VRX) opened at 14.46 on Wednesday. The stock’s market capitalization is $5.04 billion. The stock has a 50 day moving average of $14.01 and a 200 day moving average of $13.42. Valeant Pharmaceuticals International has a 52 week low of $8.31 and a 52 week high of $24.30.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last posted its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.97 by $0.08. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. The firm had revenue of $2.23 billion for the quarter, compared to the consensus estimate of $2.23 billion. During the same quarter in the previous year, the company earned ($0.88) earnings per share. The business’s revenue was down 7.7% compared to the same quarter last year. On average, equities research analysts predict that Valeant Pharmaceuticals International will post $3.89 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This article was posted by Watch List News and is the property of of Watch List News. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.watchlistnews.com/valeant-pharmaceuticals-international-inc-vrx-earns-hold-rating-from-hc-wainwright-2/1614971.html.

In other Valeant Pharmaceuticals International news, Director Schutter Richard U. De acquired 10,000 shares of the firm’s stock in a transaction that occurred on Monday, August 21st. The stock was acquired at an average cost of $14.33 per share, for a total transaction of $143,300.00. Following the transaction, the director now owns 77,479 shares of the company’s stock, valued at $1,110,274.07. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.87% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Gruss & Co. Inc. bought a new stake in Valeant Pharmaceuticals International in the 1st quarter valued at approximately $104,000. Harbor Advisors LLC bought a new stake in Valeant Pharmaceuticals International in the 1st quarter valued at approximately $110,000. NEXT Financial Group Inc lifted its stake in Valeant Pharmaceuticals International by 6.2% in the 2nd quarter. NEXT Financial Group Inc now owns 10,303 shares of the specialty pharmaceutical company’s stock valued at $178,000 after acquiring an additional 600 shares in the last quarter. Financial Architects Inc lifted its stake in Valeant Pharmaceuticals International by 10.5% in the 2nd quarter. Financial Architects Inc now owns 10,550 shares of the specialty pharmaceutical company’s stock valued at $183,000 after acquiring an additional 1,000 shares in the last quarter. Finally, PNC Financial Services Group Inc. lifted its stake in Valeant Pharmaceuticals International by 33.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 10,965 shares of the specialty pharmaceutical company’s stock valued at $121,000 after acquiring an additional 2,763 shares in the last quarter. Hedge funds and other institutional investors own 50.48% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.